Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2015

Planlagt Fastgjort Låst Flyttet Genmab
988 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #366

    ASCO nærmer sig og snart får vi syn for sagen - i hvert fald angående safety

    1 Reply Last reply
    0
    • investor1989I Offline
      investor1989I Offline
      investor1989
      wrote on sidst redigeret af
      #367

      ja vi får abstract release + J&J R&D dag

      1 Reply Last reply
      0
      • Legolas23L Offline
        Legolas23L Offline
        Legolas23
        wrote on sidst redigeret af
        #368

        Jeg synes at erindre, at vi har hjørt Jan sige, at der er styr på safety i forbindelse med TF-ADC.

        1 Reply Last reply
        0
        • Legolas23L Offline
          Legolas23L Offline
          Legolas23
          wrote on sidst redigeret af
          #369

          Det er klart, at selvsyn virker bedre til ASCO, men han har vist ladet et par kommentarer falde omkring safety

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #370

            Han har sagt at så længe det kliniske studie ikke stopper, så er det i hvert fald tegn på at tingene indtil videre ser ud som det skal

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #371

              Det kunne også være ret cool, men sikkert en for lille ting at forvente på JNJ R&D dag, hvis der kom en udmelding om vi ser et Janssen DuoBody i klinik i år

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #372

                Genmab holder sig godt oppe i dagen sure marked

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #373

                  Jeps. Har været i møder hele dagen. Ser nu rødt..Men Genmab klarer sig fint.

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #374

                    BMY har i dag meddelt at de stopper et fase 3 med opdivo. MedWatc skriber at stoffet - et pd-1 hæmmer antistof forventes at omsætte for 5,7 mia usd allerede i 2019. Gamle Medarex ejere må græmme sig endnu engang for den foræring bmy fik for år tilbage - sølle 2 mia usd for Genmabs moder 😞 http://www.natap.org/2007/HCV/103007_01.htm

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #375

                      medWatch skriver ....

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #376

                        ...vel at mærke stoppet førtidigt pga god effekt http://finance.yahoo.com/news/bristol-myers-big-drug-study-142312369.html

                        1 Reply Last reply
                        0
                        • D Offline
                          D Offline
                          dohk
                          wrote on sidst redigeret af
                          #377

                          Tro mig Solsen, jeg piver tit over det salg. De 2 mia usd var vel at mærke for 1 mia usd cash plus resten biksen. Har puttet penge i BMY men det giver jo ikke en x30 eller hvad MEDX skulle være værd i dag...

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #378

                            Ja det var rent galmandsværk !!!

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #379

                              Vejle hospital laver nyt studie med Daratumumab (!). "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab " (DARA)https://clinicaltrials.gov/ct2/show/NCT02419118?term=daratumumab&rank=5&submit_fld_opt=

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #380

                                The effector mechanisms of daratumumab have been extensively studied in vitro, but the in vivo correlates and key determinants of success or failure when daratumumab is used alone or in combination with lenalidomide for treatment of patients with myeloma have not been clarified.

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #381

                                  There is potentially a wide spectrum of factors that may influence the quality and duration of response following treatment with daratumumab. The integrity of the patient's immune system may be important. Prior lines of chemotherapy or the myeloma disease itself may impair humural (i.e. complement) or cellular (i.e. ADCC) effector mechanisms that are of importance for the response to daratumumab.

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #382

                                    NYT studie med ofatumumab med M.D.Anderson Cancer Center: Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma.

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #383

                                      The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in patients who are 12-30 years of age

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #384

                                        Hence, our data reinforce the idea of active suppression of antitumor responses by Tregs in MM patients and therefore suggest that targeting patient Tregs before DLI may improve outcome of DLI.Bone Marrow Transplantation advance online publication, 23 March 2015; doi:10.1038/bmt.2015.48.

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #385

                                          http://www.futuremedicine.com/doi/abs/10.2217/imt.12.116 Mere om Tregs

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger